Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell mal…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma [EARLY_Phase 1]
Early-phase clinical trial update on the safety, efficacy and metabolic kinetics of CT1182 injection in relapsed/refractory non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]
Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma [Phase 3]
Phase 3 clinical trial comparing rituximab and mosunetuzumab for low tumor burden follicular lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma [Phase 2]
Phase 2 study of Gazyvaro (obinutuzumab) with low-dose radiotherapy in early-stage follicular lymphoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma [Phase 2]
Phase 2 trial at MD Anderson evaluating a combination of acalabrutinib, lenalidomide, and rituximab for CD20-positive follicular lymphoma at…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma [Phase 2]
This is a Phase 2 clinical trial update evaluating a three-drug combination of obinutuzumab, ibrutinib, and venetoclax for previously untrea…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial update describes a study evaluating whether odronextamab combined with lenalidomide is safe and more effective than…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy for relapsed or refract…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial of tazemetostat plus venetoclax for relapsed/refractory non-Hodgkin lymphoma has been terminated, including diffuse l…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma [Phase 2]
Phase 2 trial comparing ZR2 versus R2 regimen in newly diagnosed follicular lymphoma; currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial assessed first-line therapy combining bortezomib, chemotherapy, and rituximab in patients with stage III or IV follicular ly…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma [Phase 1]
This report covers a Phase 1 clinical trial evaluating a personalized neoantigen cancer vaccine in combination with pembrolizumab after ritu…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) [Phase 1]
A Phase 1 study of LY4152199 in previously treated B-cell cancers is listed, with the trial currently NOT_YET_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma [Phase 3]
A Phase 3 trial evaluating the combination of ibrutinib and rituximab in treatment-naïve follicular lymphoma has completed and posted result…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]
Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been t…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating glofitamab and obinutuzumab in indolent non-Hodgkin lymphomas, including follicular lymphoma and marginal …
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.